Your browser doesn't support javascript.
loading
Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND).
Shi, Vivian Y; Bhutani, Tina; Fonacier, Luz; Deleuran, Mette; Shumack, Stephen; Valdez, Hernan; Zhang, Fan; Chan, Gary L; Cameron, Michael C; Yin, Natalie C.
Affiliation
  • Shi VY; Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Bhutani T; Department of Dermatology, University of California San Francisco, San Francisco, California.
  • Fonacier L; New York University Langone Hospital-Long Island, New York, New York.
  • Deleuran M; Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
  • Shumack S; Department of Dermatology, University of Sydney, Royal North Shore Hospital, Sydney, Australia.
  • Valdez H; Pfizer Inc, New York, New York.
  • Zhang F; Pfizer Inc, Groton, Connecticut.
  • Chan GL; Pfizer Inc, Groton, Connecticut. Electronic address: gary.chan@pfizer.com.
  • Cameron MC; Pfizer Inc, New York, New York.
  • Yin NC; Pfizer Inc, New York, New York.
J Am Acad Dermatol ; 87(2): 351-358, 2022 08.
Article in En | MEDLINE | ID: mdl-35439608
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dermatitis, Atopic / Eczema Type of study: Clinical_trials Limits: Adult / Humans Language: En Journal: J Am Acad Dermatol Year: 2022 Document type: Article Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dermatitis, Atopic / Eczema Type of study: Clinical_trials Limits: Adult / Humans Language: En Journal: J Am Acad Dermatol Year: 2022 Document type: Article Country of publication: Estados Unidos